New market study, "Jordan Pharmaceuticals & Healthcare Report Q4 2014", has been published

From: Fast Market Research, Inc.
Published: Tue Sep 09 2014


This quarter has seen the extension of GlaxoSmithKline's bribery allegation investigations . These now span the Gulf Levant, bringing Jordan's pharmaceutical industry into the spotlight. We do not believe Jordan will attract interest from innovative drugmakers in 2014 and project low single-digit growth in the market. This growth forecast is based on our expectations for weak government spending, the JFDA's recent medicine price cuts and weak pharmaceutical import growth in 2013.

Headline Expenditure Projections

* Pharmaceuticals: JOD641mn (USD905mn) in 2013 to JOD664mn (USD937mn) in 2014; +3.6% in local currency terms and +3.5% in US dollar terms. Forecast revised slightly downwards due to macroeconomic factors.
* Healthcare: JOD2.08bn (USD2.94bn) in 2013 to JOD2.27bn (USD3.21bn) in 2014; +9.2% in local currency terms and +9.1% in US dollar terms. Forecast revised slightly downwards due to macroeconomic factors.

Full Report Details at
- http://www.fastmr.com/prod/872626_jordan_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Risk/Reward Rating

In our Q314 Risk/Reward Ratings matrix, Jordan maintains its position of 10thout of 30 markets surveyed in the Middle East and Africa (MEA) region, despite receiving a lower score of 48.6 out of 100. Generally speaking, although Jordan offers a relatively favourable investment environment in terms of Risks, its small population size (of around seven million) limits potential pharmaceutical market growth.

Key Trends And Developments

April 2014

* GlaxoSmithKline (GSK) reported in a statement on April 23 that it is investigating allegations that is offered bribes, free samples and travel benefits to doctors and officials in Jordan and Lebanon to encourage them to use its medicines. GSK is present in the Jordanian market through imports, which are distributed by domestic companies. These allegations follow earlier claims of corruption in China, Poland and Iraq.
* Local drugmaker Hikma Pharmaceuticals received a close-out letter from the FDA that lifted the warning letter received in February 2012 regarding its...

The Jordan Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Jordan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Jordanian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Jordan to test other views - a key input for successful budgeting and strategic business planning in the Jordanian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014
- Peru Pharmaceuticals & Healthcare Report Q4 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »